Predicting relapse in chronic spontaneous urticaria: A retrospective cohort study evaluating omalizumab withdrawal regimens

Affiliations

¹ Department of Internal Diseases, Pneumonology, Allergology and Clinical Immunology, Military Institute of Medicine - National Research Institute, Warszawa, Poland.
² Medical Faculty I, Medical University of Warsaw, Warszawa, Poland.
³ HTA Consulting, Kraków, Poland.
⁴ Department of Infectious Diseases and Allergology, Military Institute of Medicine - National Research Institute, Warszawa, Poland.
⁵ Department of Dermatology, Military Institute of Medicine - National Research Institute, Warszawa, Poland.

Aleksandra Kucharczyk et al. Allergy. 2024 Sep.

. 2024 Sep;79(9):2554-2557.

doi: 10.1111/all.16194. Epub 2024 Jun 24.

¹ Department of Internal Diseases, Pneumonology, Allergology and Clinical Immunology, Military Institute of Medicine - National Research Institute, Warszawa, Poland.
² Medical Faculty I, Medical University of Warsaw, Warszawa, Poland.
³ HTA Consulting, Kraków, Poland.
⁴ Department of Infectious Diseases and Allergology, Military Institute of Medicine - National Research Institute, Warszawa, Poland.
⁵ Department of Dermatology, Military Institute of Medicine - National Research Institute, Warszawa, Poland.

No abstract available

Keywords: chronic spontaneous urticaria; omalizumab; relapse; risk factors; withdrawal.

References

1. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77:734‐766. doi:10.1111/all.15090
1. Yu R, Qian W, Zheng Q, et al. Analysis of the efficacy and recurrence of omalizumab use in the treatment of chronic spontaneous urticaria and chronic inducible urticaria. Int Arch Allergy Immunol. 2023;184(7):643‐655. doi:10.1159/000529250
1. Marzano AV, Genovese G, Casazza G, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. J Eur Acad Dermatol Venereol. 2018;33(5):918‐924. doi:10.1111/jdv.15350
1. Türk M, Yılmaz İ, Bahçecioğlu SN. Treatment and retreatment with omalizumab in chronic spontaneous urticaria: real life experience with twenty‐five patients. Allergol Int. 2018;67(1):85‐89. doi:10.1016/j.alit.2017.05.003
1. Türk M, Carneiro‐Leão L, Kolkhir P, Bonnekoh H, Buttgereit T, Maurer M. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers. J Allergy Clin Immunol Pract. 2020;8(1):113‐124. doi:10.1016/j.jaip.2019.07.021